FAIR VALUE DISCLOSURES (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of recurring Level 3 fair value measurements of contingent consideration

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

Payment Type	Valuation Technique	Unobservable Input	Assumptions
Profit-based milestone payments	Probability-weighted discounted cash flow	Discount rate	13.0%
		Projected fiscal year of payment	2025-2035
Product development-based milestone payments	Probability-weighted discounted cash flow	Discount rate	7.0% - 13.0%
		Probability of payment	100.0%
		Year of payment	2024

Schedule of changes in contingent consideration

The following table presents the changes in contingent consideration balances classified as Level 3 for the three months ended March 31, 2024 and 2023:

	Three Months Ended March 31,
(in thousands)	2024		2023
Beginning balance	$	23,984	$	35,058
Payment of Gross-Profit earn-out	(12,500)		—
Change in fair value	90		961
Ending balance	$	11,574	$	36,019

Schedule of financial assets and liabilities accounted for at fair value on a recurring basis

The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023, by level within the fair value hierarchy:

(in thousands) Description	Fair Value at March 31, 2024		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	174,316	$	174,316	$	—	$	—
Interest rate swap	$	7,654	$	—	$	7,654	$	—
CG Oncology - Investment in equity securities	$	9,655	$	9,655	$	—	$	—
Liabilities
Contingent consideration	$	11,574	$	—	$	—	$	11,574

Description	Fair Value at December 31, 2023		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	194,841	$	194,841	$	—	$	—
Interest rate swap	$	6,236	$	—	$	6,236	$	—
Liabilities
Contingent consideration	$	23,984	$	—	$	—	$	23,984